NEW YORK, Nov. 17 /PRNewswire-FirstCall/ -- Medicsight (BULLETIN BOARD: MSHT) announced today the appointment of Susan Wood as Chief Operating Officer. Wood has a strong pedigree in the medical imaging sector, and her wealth of professional experience will be a valuable addition to the company. She will focus heavily on Medicsight's product development strategy, helping it realize its vision of advancing computer-aided detection software to full computer-aided diagnosis software.
"Medicsight is continuously looking toward the future and striving to achieve our goal of being the leading global supplier of medical imaging analysis software," said Paul Samuel, Medicsight CEO. "As our company continues to grow, Susan's skills will be instrumental in helping us maintain our position of leadership in this sector."
Wood said she is excited to join Medicsight. "The emphasis on strategic vision and growth has given this company the potential to make a groundbreaking impact on the medical imaging marketplace. I look forward to contributing to an already impressive team of medical and business partners as we a work together to ensure a promising future for Medicsight."
Wood joins Medicsight after more than a decade within the sector, most recently serving as vice president of computed tomography (CT) products and marketing at R2 Technology, Inc. Wood has co-authored multiple publications and U.S. patent applications in computer-aided diagnosis.
"Medicsight has a unique product portfolio currently focusing on heart, colon, and lung imaging," said Jamshid Dehmeshki, Medicsight Chief Technology Officer. "Susan's depth of knowledge will enable us to deliver additional products quickly to the marketplace, broadening our offering to focus on different disease areas and modalities."
The position of Chief Operating Officer became effective November 15, 2004 and is based in Medicsight's New York City office.
Medicsight is a software development business focused on the medical imaging market. The company is using its core technology to develop automatic detection and analytical tools for clinicians to improve their ability to diagnose and treat disease. Medicsight has initially focused on three key clinical areas -- lung cancer, colon cancer, and coronary heart disease -- which together account for almost half of all deaths in America. Medicsight's software will enable earlier and more accurate detection and treatment of suspicious lesions, which can save lives and reduce healthcare costs. Headquartered in London, Medicsight employs more than 60 people and has offices in New York City, Nashville, Tenn., and China. Since its inception in 1999, Medicsight has been developing its core algorithms through a team of more than 30 scientists and software developers. For further information, please visit http://www.medicsight.com/. Stock symbol: MSHT
MedicsightCONTACT: Cara Ramsay of Fleishman-Hillard, +1-314-982-7772, forMedicsight; or David Sumner, International Marketing Director,+44-20-7598-4080, or David Mason, Investor Relations, +1-615-665-9007, both ofMedicsight
Web site: http://www.medicsight.com/
